Labcorp Holdings Inc. has announced its financial results for the second quarter of 2025, reporting an increase in revenue to $3.53 billion compared to $3.22 billion in the same period in 2024. The company's diluted earnings per share $(EPS)$ rose to $2.84 from $2.43, and the adjusted EPS increased to $4.35 from $3.94 year-over-year. Labcorp has updated its full-year guidance, raising its enterprise revenue growth range to 7.5% to 8.6%, with the midpoint increased by 70 basis points. The adjusted EPS guidance has been narrowed to a range of $16.05 to $16.50, with the midpoint raised by $0.23. The free cash flow forecast is now between $1.13 billion to $1.28 billion, with the midpoint increased by $25 million. The company has broadened its partnerships with hospitals, health systems, and regional/local labs, enhancing access to comprehensive testing and laboratory services. Additionally, Labcorp has introduced several new tests in high-growth specialty areas, including oncology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.